Analyzing Cyclacel Pharmaceuticals (BGMS) & Its Peers

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Cyclacel Pharmaceuticals to similar businesses based on the strength of its profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares Cyclacel Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$40,000.00	-$11.21 million	-0.02
Cyclacel Pharmaceuticals Competitors	$434.13 million	-$68.27 million	-10.75

Cyclacel Pharmaceuticals’ peers have higher revenue, but lower earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Cyclacel Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Cyclacel Pharmaceuticals Competitors	4860	9973	15986	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 121.21%. Given Cyclacel Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Cyclacel Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Cyclacel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Cyclacel Pharmaceuticals Competitors	-2,626.20%	-359.54%	-43.35%

Risk and Volatility

Cyclacel Pharmaceuticals has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals’ peers have a beta of 11.32, meaning that their average share price is 1,032% more volatile than the S&P 500.

Summary

Cyclacel Pharmaceuticals peers beat Cyclacel Pharmaceuticals on 8 of the 13 factors compared.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.